Form 4: Alzamend Neuro Director Milton C. Ault III Reports Stock Purchase

Milton C. Ault III, a director and 10% owner of Alzamend Neuro, Inc., reported purchasing 334 shares of common stock at $0.9109 per share on April 1, 2024.

Summary

• On April 1, 2024, Milton C. Ault III, a director and 10% owner of Alzamend Neuro, Inc. (ALZN), purchased 334 shares of common stock at a price of $0.9109 per share.
• Following this transaction, Ault directly owns 166,865 shares of common stock.
• Ault also indirectly owns 770,699 shares through Ault Lending, LLC, 996,197 shares through Ault Life Sciences, Inc., and 5,498 shares through Ault Life Sciences Fund, LLC.
• Mr. Ault has voting and investment power over the shares held by Ault Lending, LLC, Ault Life Sciences, Inc., and Ault Life Sciences Fund, LLC.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. The purchase could be seen as a positive signal, but without more context, it's difficult to assess the overall impact.

Positives

• The director's purchase of shares may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders.

Stakeholder Impact

• The stock purchase by a director could positively influence investor sentiment.

Key Dates

Keywords

Alzamend Neuro, ALZN, Milton C. Ault III, stock purchase, Form 4, director, beneficial ownership, Ault Lending, Ault Life Sciences, insider trading